ssDNA
Leveraging the Therapeutic Potential of Single-Stranded DNA
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-07-25-NI-10Jul 23, 2025
Gene Editing
What are the key ethical and regulatory considerations as gene editing technologies advance toward widespread clinical use?
Pharma's Almanac
PAO-05-25-RT-02Jun 17, 2025
Xenotransplantation
CRISPR-Edited Pig Organs and the Promise of Xenotransplantation
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-25-NI-13Apr 25, 2025
Gene Therapy
Gene Therapy at 30: Milestones, Setbacks, and a Path Forward
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-25-30-28Apr 14, 2025
RNA
Beyond mRNA Vaccines: The Expanding World of RNA-Based Therapeutics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-24Mar 21, 2025
Small Biotechs
Five Small Biotechs to Watch: March 2025
David Alvaro, Ph.D.
Pharma's Almanac
PAO-02-25-NI-06Feb 28, 2025
CASGEVY
Orsini Now Distributing CASGEVY® (exagamglogene autotemcel), a Gene-Editing Therapy
Orsini Healthcare
PR-11-24-NI-103Nov 15, 2024
CRISPR
The Groundbreaking Potential of CRISPR Gene Editing
Olivia Newton-John Cancer Research Institute
PAO-10-24-RTM-09Nov 05, 2024
Gene Editing
MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing
Tom Adie, Ph.D.; Elena Stoyanova, Ph.D.
Touchlight
PAO-10-24-CL-01Sep 30, 2024
Lipid Nanoparticle Development
Lipid Technology for Delivery of Gene-Editing Therapies
Stephen Burgess, Ph.D.
Croda Pharma
PAO-11-022-CL-18Jan 17, 2023
Antibiotic Resistance
Antibiotic Resistance: Advances in Understanding and Drug Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-022-NI-07Oct 11, 2022
mRNA
Limitless Potential of mRNA Creates Tremendous Excitement Despite Uncertainties
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-10-022-NI-02Oct 11, 2022
CRISPR Research Innovation
A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors
Gladstone Institutes
PR-M08-22-05Aug 25, 2022
Regulatory
FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review
U.S. Food & Drug Administration
PR-M03-22-03Mar 07, 2022
Gene Editing
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
Prime Medicine
PA852Jul 16, 2021
Gene Editing
Enabling Gene-Edited hMSCs with a Fit-for-Purpose Transduction Agent
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-21-CL-06Jul 15, 2021
Collaboration
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
Vertex
PR-M04-21-024Apr 22, 2021
Gene Editing
Enhancing Human Gut Tissue Models through Gene Editing
Scott Magness, Ph.D.
Altis Biosystems
PAO-11-20-CL-03Nov 30, 2020
CRISPR RNPs
CRISPR RNPs and the Future of Cell and Gene Therapy
Thomas Lynch, Ph.D.
Aldevron
PAP-Q3-20-CL-002Sep 29, 2020
Gene Therapy
Slow Progress and a Shaky Start—What’s Next for Gene Therapy?
Nigel Walker
Nice Insight
PAP-Q4-19-NI-001Dec 06, 2019